Sutro Biopharma, Inc.
310 Utah Avenue
South San Francisco
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. develops best-in-class antibody-drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Sutro’s discovery and development efforts are driven by the Xpress CF™ platform, a biochemical synthesis system that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro’s make-test cycle for hundreds of protein variants, including those incorporating non-natural amino acids, takes approximately two weeks, enabling broader and deeper biologics discovery and development efforts than can be accomplished with current cell-based expression technologies. Sutro’s technology platform allows production of proteins by bypassing the cell completely, cutting the pre-clinical development period by several months and can be done on any scale in just 8-10 hours.
Once identified, production of protein drug candidates can be rapidly and predictably scaled in Sutro’s cGMP manufacturing facility located in San Carlos, CA. Importantly, Xpress CF™ was nominated for best scientific innovation by World ADC in 2014 and Sutro Biopharma was named one of FierceBiotech’s Fierce 15 in 2014.
In addition to developing its own drug pipeline, Sutro Biopharma is collaborating with select pharmaceutical and biotech companies to discover and develop novel therapeutics. Last year, Sutro partnered with both Celgene and EMD Serono. This second partnership with Celgene is a multi-year collaboration focused on immuno-oncology and is valued at over $1 Billion. In the agreement, Celgene has an exclusive option to acquire Sutro. The deal with EMD Serono is a $300M+ collaboration to discover and develop novel antibody-drug conjugates for several targets in the field of oncology.
• William J. Newell, JD, CEO
• Trevor Hallam, PhD, Chief Scientific Officer
• Ed Albini, Chief Financial Officer
• Henry Heinsohn, VP Development & Manufacturing
• Aaron Sato, PhD, VP Research
• Nicki Vasquez, PhD, VP Alliance/Project Management
124 articles with Sutro Biopharma, Inc.
A New Generation of Precisely Engineered CD74-Targeting ADC
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
Sutro Biopharma, Inc. today announced the pricing of its initial public offering of 5,667,000 shares of its common stock at a price to the public of $15.00 per share.
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
Only a month after raising $85.4 million in a Series E financing, Sutro Biopharma filed for an initial public offering (IPO). The company plans to raise $75 million with the IPO.
Sutro Biopharma, Inc., and The Leukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro’s CD74-targeting antibody-drug conjugate, to treat relapsed and/or refractory multiple myeloma and non-Hodgkin’s lymphoma.
Sutro Biopharma, Inc., has secured $85.4 million in Series E financing to advance its wholly-owned pipeline of novel cancer therapeutics, including two internally-developed antibody drug conjugates, or ADCs, known as STRO-001, now in Phase 1 clinical testing for lymphoma and multiple myeloma, and STRO-002, which is expected to enter clinical trials for ovarian and endometrial cancer by early 2019.
Sutro's Cell-free Protein Synthesis Technology is Paired With Merck's Immunology & Cancer Expertise
Sutro plans to submit an investigational new drug application by the end of 2017 and to launch a Phase 1 clinical trial in the first quarter of 2018 to evaluate the safety and preliminary efficacy of STRO-001 in patients with multiple myeloma and aggressive and indolent, or slow-growing, lymphomas.
Sutro Biopharma ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival In Tumor Models
Sutro Biopharma ADC Targeting CD74 Exhibits Potent Anti-Tumor Activity In Multiple Malignant Cell Lines And Animal Models Of Non-Hodgkin Lymphoma And Multiple Myeloma
Sutro Biopharma ADCs Targeting CD74 Suppress Tumors In Multiple Malignant Cell Lines And Animal Models Of Multiple Myeloma And Non-Hodgkin Lymphoma
Sutro Biopharma Expands Senior Leadership Team With Addition Of Chief Medical Officer And VP Of Translational Pharmacology And Preclinical Development
Sutro Biopharma Receives The Pantheon 2015 DiNA Outstanding Partner Award By The California Life Sciences Association